- Chemotherapy
- Immunotherapy
Non-Hodgkin Lymphoma Treatment Market size was valued at USD 478.90 and is poised to grow at a significant CAGR of 7.25% from 2023-2029. Non-Hodgkin lymphoma is caused by a combination of factors including age, gender, exposure to chemicals such as benzene and pesticides, a compromised immune system, and chemical exposure. Over the forecast period, increased awareness of cancer diagnosis and treatment, as well as government intervention with various cost-effective policies, are likely to enhance the Non-Hodgkins Lymphoma (NHL) market. Despite the fact that numerous medications are available for NHL, none of them are effective at the end stage, which may limit the growth of the non-hodgkin lymphoma treatment market throughout the projection period. Non-Hodgkins Lymphoma (NHL) is a kind of cancer caused by aberrant B or T lymphocyte and leukocyte function. These lymphomas typically develop in the bone marrow, lymph nodes, spleen, blood, and other lymphatic organs. this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Non-Hodgkin Lymphoma Treatment Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The market is driven by factors such as demand for innovative drugs and novel technologies, FDA approval of chronic lymphocytic leukaemia therapy drugs, introduction of promising drugs such as novel small molecule inhibitors and next-generation monoclonal antibodies, and an increase in the prevalence of NHL. The expensive expense of vaccinations used in NHL therapy, as well as the negative effects associated with them, limit market expansion.
2022 is the base year and 2029 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Europe is the fastest-growing for Non-Hodgkin Lymphoma Treatment Market
Non-Hodgkin Lymphoma Treatment Market is poised to grow at a significant CAGR of 7.25%
1.Executive Summary |
2.Global Non-Hodgkin Lymphoma Treatment Market Introduction |
2.1.Global Non-Hodgkin Lymphoma Treatment Market - Taxonomy |
2.2.Global Non-Hodgkin Lymphoma Treatment Market - Definitions |
2.2.1.Treatment Type |
2.2.2.Non-Hodgkins Lymphoma Type |
2.2.3.Distribution Channel |
2.2.4.Region |
3.Global Non-Hodgkin Lymphoma Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Non-Hodgkin Lymphoma Treatment Market Analysis, 2018-2022 and Forecast 2023-2029 |
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Non-Hodgkin Lymphoma Treatment Market By Treatment Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
5.1. Chemotherapy |
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Immunotherapy |
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6.Global Non-Hodgkin Lymphoma Treatment Market By Non-Hodgkins Lymphoma Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
6.1. B-cell Lymphoma |
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. T-cell Lymphoma |
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7.Global Non-Hodgkin Lymphoma Treatment Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Others |
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Non-Hodgkin Lymphoma Treatment Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Non-Hodgkin Lymphoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
9.1. Treatment Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Chemotherapy |
9.1.2.Immunotherapy |
9.2. Non-Hodgkins Lymphoma Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.B-cell Lymphoma |
9.2.2.T-cell Lymphoma |
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Others |
9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Non-Hodgkin Lymphoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
10.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Chemotherapy |
10.1.2.Immunotherapy |
10.2. Non-Hodgkins Lymphoma Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.B-cell Lymphoma |
10.2.2.T-cell Lymphoma |
10.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Others |
10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
10.4.7. |
11.Asia Pacific (APAC) Non-Hodgkin Lymphoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
11.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Chemotherapy |
11.1.2.Immunotherapy |
11.2. Non-Hodgkins Lymphoma Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.B-cell Lymphoma |
11.2.2.T-cell Lymphoma |
11.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Others |
11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Non-Hodgkin Lymphoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
12.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Chemotherapy |
12.1.2.Immunotherapy |
12.2. Non-Hodgkins Lymphoma Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.B-cell Lymphoma |
12.2.2.T-cell Lymphoma |
12.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Others |
12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Non-Hodgkin Lymphoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
13.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Chemotherapy |
13.1.2.Immunotherapy |
13.2. Non-Hodgkins Lymphoma Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.B-cell Lymphoma |
13.2.2.T-cell Lymphoma |
13.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Others |
13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.F. Hoffmann-La Roche AG |
14.2.2.Seattle Genetics |
14.2.3.Spectrum Pharmaceuticals |
14.2.4.Celgene |
14.2.5.Millennium/Johnson-Johnson |
14.2.6.Merck Inc. |
14.2.7.Pharmacyclics/Janssen Biotech |
14.2.8.Kyowa Hakko Kirin |
14.2.9.CTI Biopharma |
15. Research Methodology |
16. Appendix and Abbreviations |